Yumanity and NY Stem Cell Foundation Announce Discovery Collaboration

Yumanity Therapeutics, a biotechnology company focused on drug discovery for neurodegenerative diseases associated with protein misfolding, has announced a partnership with the NY Stem Cell Foundation (NYSCF) Research Institute to generate induced pluripotent stem cell (iPSC) lines for applications in drug discovery for ALS, Alzheimer’s and Parkinson’s disease (see Feb 2016 news). Yumanity will leverage NYSCF’s Global Stem Cell Array technology for large scale production of standardized iPSCs to incorporate into the company’s drug discovery platform, which integrates high-throughput phenotypic screening in yeast cells with drug candidate validation in human patient-derived iPSCs.

Click here to read the press release.

disease-ad disease-als disease-pd iPSC New York Stem Cell Foundation NYSCF topic-preclinical topic-randd yumanity
Share this: